Arnon Nagler

1 week ago | nature.com | Arnon Nagler |Nicolaus Kröger |Matthias Stelljes |Johan Maertens |Gesine Bug |Didier Blaise | +3 more

AbstractThe cytogenetic risk category retains a pivotal role in the prediction of prognosis in acute myeloid leukemia (AML) patients undergoing hematopoietic stem cell transplantation (HSCT), however, its impact on secondary AML (sAML) is less established. We assessed whether the ELN 2022 cytogenetic risk score predicts outcomes in sAML patients in remission undergoing HSCT from HLA-matched donors performed between 2010 and 2022.

Jan 5, 2024 | chi.scholasticahq.com | Mohamad Mohty |Arnon Nagler |Bipin N. Savani

The International Academy for Clinical Hematology (IACH) was conceived by an international group of physicians whose focus is to promote good clinical practice in the field of hematology. The IACH was launched in 2018 but, at that time, many colleagues were skeptical about the concept of using digital tools to spread and disseminate knowledge and education.

Dec 12, 2023 | nature.com | Xavier Poiré |Myriam Labopin |Gerard Socie |Edouard Forcade |Yves Chalandon |Mahmoud Aljurf | +3 more

AbstractAllogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML.

Oct 2, 2023 | onlinelibrary.wiley.com | Jenny Byrne |Frédéric Baron |Arnon Nagler |Jacques-Emmanuel Galimard

CONFLICT OF INTEREST STATEMENT FB has received travel grants and/or speaker honoraria from Celgene, Abbvie, Novartis, Pfizer and Sanofi. The other authors declare that they have no relevant conflict of interest. REFERENCES 1, . Optimizing outcomes in secondary AML. Hematology Am Soc Hematol Educ Program. 2022; 2022: 23–29. 2, , , , , , et al. Survival improvement over time of 960 s-AML patients included in 13 EORTC-GIMEMA-HOVON trials. Cancer. 2020; 12(11): 3334. 3, , , , , , et al.

Sep 2, 2023 | nature.com | Arnon Nagler |Nicolaus Kröger |Georg-Nikolaus Franke |Gerard Socie |Johannes Schetelig |Fabio Ciceri

AbstractWe compared outcomes, of 1609 patients with secondary acute myeloid leukemia (sAML) undergoing allogeneic transplantation (HSCT) in first complete remission (CR1) from matched unrelated donors (MUD) from 2010 to 2021, receiving or not receiving anti-thymocyte globulin (ATG) (ATG-1308, no ATG-301). Median age was 60.9 (range, 18.5–77.8) and 61.1 (range, 21.8–75.7) years, (p = 0.3).